BioCryst Pharmaceuticals, Inc. (BCRX)

BioCryst Pharmaceuticals Statistics

Total Valuation

BCRX has a market cap or net worth of $2.16 billion. The enterprise value is $2.70 billion.

Market Cap	2.16B
Enterprise Value	2.70B

Important Dates

The last earnings date was Monday, May 5, 2025, before market open.

Earnings Date	May 5, 2025
Ex-Dividend Date	n/a

Share Statistics

BCRX has 209.25 million shares outstanding. The number of shares has increased by 5.50% in one year.

Current Share Class	209.25M
Shares Outstanding	209.25M
Shares Change (YoY)	+5.50%
Shares Change (QoQ)	+3.80%
Owned by Insiders (%)	1.04%
Owned by Institutions (%)	76.26%
Float	195.20M

Valuation Ratios

PE Ratio	n/a
Forward PE	35.00
PS Ratio	4.26
Forward PS	3.60
PB Ratio	-4.79
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	5.36
EV / EBITDA	71.99
EV / EBIT	78.34
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.93

Current Ratio	2.93
Quick Ratio	2.78
Debt / Equity	n/a
Debt / EBITDA	20.87
Debt / FCF	n/a
Interest Coverage	0.35

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	4.54%
Return on Invested Capital (ROIC)	5.71%
Return on Capital Employed (ROCE)	10.12%
Revenue Per Employee	$868,078
Profits Per Employee	-$92,190
Employee Count	580
Asset Turnover	1.06
Inventory Turnover	9.82

Taxes

In the past 12 months, BCRX has paid $2.29 million in taxes.

Income Tax	2.29M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +94.36% in the last 52 weeks. The beta is 1.08, so BCRX's price volatility has been similar to the market average.

Beta (5Y)	1.08
52-Week Price Change	+94.36%
50-Day Moving Average	8.00
200-Day Moving Average	7.87
Relative Strength Index (RSI)	68.63
Average Volume (20 Days)	6,247,430

Short Selling Information

The latest short interest is 18.30 million, so 8.74% of the outstanding shares have been sold short.

Short Interest	18.30M
Short Previous Month	20.44M
Short % of Shares Out	8.74%
Short % of Float	9.37%
Short Ratio (days to cover)	6.59

Income Statement

In the last 12 months, BCRX had revenue of $503.49 million and -$53.47 million in losses. Loss per share was -$0.26.

Revenue	503.49M
Gross Profit	323.48M
Operating Income	34.44M
Pretax Income	-146.50M
Net Income	-53.47M
EBITDA	37.47M
EBIT	34.44M
Loss Per Share	-$0.26

Balance Sheet

The company has $295.09 million in cash and $829.29 million in debt, giving a net cash position of -$534.20 million or -$2.55 per share.

Cash & Cash Equivalents	295.09M
Total Debt	829.29M
Net Cash	-534.20M
Net Cash Per Share	-$2.55
Equity (Book Value)	-451.93M
Book Value Per Share	-2.16
Working Capital	270.12M

Cash Flow

In the last 12 months, operating cash flow was -$25.85 million and capital expenditures -$1.03 million, giving a free cash flow of -$26.89 million.

Operating Cash Flow	-25.85M
Capital Expenditures	-1.03M
Free Cash Flow	-26.89M
FCF Per Share	-$0.13

Margins

Gross margin is 64.25%, with operating and profit margins of 6.84% and -10.62%.

Gross Margin	64.25%
Operating Margin	6.84%
Pretax Margin	-10.17%
Profit Margin	-10.62%
EBITDA Margin	7.44%
EBIT Margin	6.84%
FCF Margin	n/a

Dividends & Yields

BCRX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-5.50%
Shareholder Yield	-5.50%
Earnings Yield	-2.47%
FCF Yield	-1.24%

Analyst Forecast

The average price target for BCRX is $16.75, which is 61.99% higher than the current price. The consensus rating is "Buy".

Price Target	$16.75
Price Target Difference	61.99%
Analyst Consensus	Buy
Analyst Count	8
Revenue Growth Forecast (5Y)	15.80%
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BCRX has an Altman Z-Score of -2.24 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.24
Piotroski F-Score	5